Phase 2
Completed N=31
A Study to Evaluate Multiple Oral Doses of Luvadaxistat in Adults With Schizophrenia
Source: ClinicalTrials.gov NCT03359785 ↗Enrolled (actual)
31
Serious AEs
0.0%
Results posted
Feb 2024
Primary outcomePrimary: Change From Baseline in Average Percent of Conditioned Responses During the Eye Blink Conditioning (EBC) Test at Day 8 — 0.597; 0.319; 0.578; 1.344 Percent of Conditioned Responses — p=0.2401
Summary
The purpose of this study is to determine whether luvadaxistat is superior to placebo in improving cerebellar function as measured with the average percentage of conditioned responses during the eyeblink conditioning (EBC) test.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline in Average Percent of Conditioned Responses During the Eye Blink Conditioning (EBC) Test at Day 8 |
0.597; 0.319; 0.578; 1.344 | 0.2401 |
| SECONDARY Change From Baseline in the Mean Mismatch Negativity (MMN) at Day 8 |
-0.239; 0.669; 0.594; -0.154 | — |
| SECONDARY Change From Baseline in the Mean P300 Amplitude at Day 8 |
-2.019; 0.608; 1.102; 2.595 | — |
| SECONDARY Change From Baseline in the Mean Auditory Steady State Response (ASSR) at Day 8 |
2.135; -16.282; 9.411; 9.203 | — |
| SECONDARY Change From Baseline on the Brief Assessment of Cognition in Schizophrenia (BACS) Composite Score at Day 7 |
2.574; 5.070; 5.696; -0.075 | — |
| SECONDARY Change From Baseline in the Mean Plasma Concentrations of D-serine and L-serine at Day 8 |
0.0402; -0.000892; 0.0398; 0.00212; 0.669; -0.543 | — |
| SECONDARY Change From Baseline in the Mean Plasma D-serine to Total Serine Ratio at Day 8 |
0.00293; 0.000590; 0.00561; 0.000620 | — |
| SECONDARY Mean Plasma Concentration of Luvadaxistat |
253.4; 700.4; 47.66; 671.1; 8.749; 78.92 | — |
Eligibility Criteria
Inclusion Criteria
- Have a body mass index (BMI) greater than or equal to (>=) 18.5 and less than or equal to ( ] 20% in dose in the preceding 2 months).
- Positive and Negative Syndrome Scale (PANSS) negative symptom factor score (NSFS) >= 15, stable screening and baseline PANSS NSFS ( 25% in dose in the preceding 2 months)antipsychotic medication at doses not to exceed risperidone 6 mg or its equivalent. Concomitant treatment with a subtherapeutic dose of a second antipsychotic may be permitted with sponsor or designee approval if used as a hypnotic (maximum of quetiapine 300 mg or its equivalent once daily at bedtime) and participants does not show morning sedation as per the investigator opinion, but not if it is used for refractory positive psychosis symptoms. Under this exception, the total daily dose the second antipsychotic will not have to be included in the calculation of the 6 mg/day risperidone-equivalent limit.
Exclusion Criteria
- Has a history of cancer (malignancy) excluding treated basal cell carcinoma or treated stage 0 (in situ) cervical carcinoma.
- Has a history of significant multiple and/or severe allergies (example [eg], food, drug, latex allergy) or has had an anaphylactic reaction or significant intolerability to prescription or nonprescription drugs or food.
- Has a QT interval with Fridericia's correction method (QTcF) > 450 milliseconds [ms] (males) or > 470 ms (females) confirmed with one repeat testing, at the Screening Visit or Check-in.
- Has a positive alcohol or drug screen for disallowed substances, including amphetamines, barbiturates, cocaine, marijuana, methadone, methamphetamine, 3,4-methylenedioxymethamphetamine, phencyclidine, or nonprescribed benzodiazepines or opiates.
- Is positive for hepatitis B surface antigen (HBsAg), hepatitis C antibodies, or has HIV by history (confirmatory testing is allowed; most sensitive test should take precedence).
- Had major surgery, donated or lost 250 milliliter [mL] of blood within 4 weeks prior to the prestudy (screening) visit.
- Has a known hypersensitivity to any component of the formulation of luvadaxistat.
- Has a history of significant skin reactions (hypersensitivity) to adhesives, metals or plastic.
- Is considered by the investigator to be at imminent risk of suicide or injury to self, others, or property, or participants who within the past year prior to Screening have attempted suicide. Participants who have positive answers on item 4 or 5 on the Columbia Suicide Severity Rating Scale (C-SSRS) (based on the past year) prior to randomization are excluded.
Data sourced from ClinicalTrials.gov (NCT03359785). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.